Cellceutix Corporation announced that enrollment has been completed in the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin as a new treatment for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease. In the trial, patients in the second cohort are being administered 100 mg of Brilacidin once daily as a retention enema for 42 consecutive days. As such, Cellceutix expects treatment of the second cohort to be completed by the end of February, 2017. Initial data from the first cohort, treated with 50 mg Brilacidin once daily showed the drug to be well-tolerated, with no measurable systemic absorption detected. Clinically meaningful improvements in symptoms were documented through endoscopic evaluation, as well as physician assessments and patient reported outcomes.